Teva Pharmaceutical Industries (TEVA) Work In Process (2009 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Work In Process for 10 consecutive years, with $590.0 million the latest figure, recorded in Q4 2018.

• Quarterly Work In Process fell 1.17% year-over-year to $590.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $590.0 million (down 1.17% YoY) and the FY2018 annual result came in at $590.0 million, down 1.17% from the prior year.
• Work In Process slipped to $590.0 million in Q4 2018 per TEVA's latest filing, from $609.0 million in the prior quarter.
• Over the last five years, Work In Process for TEVA reached as high as $734.0 million in Q2 2014 and fell as low as $475.0 million in Q2 2016.
• A 5-year average of $609.9 million and a median of $607.0 million in 2015 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2016 — Work In Process declined 25.31% — and 2017, when it gained 27.37%.
• Year by year, Work In Process stood at $638.0 million in 2014, then dropped by 16.14% to $535.0 million in 2015, then gained by 0.56% to $538.0 million in 2016, then climbed by 10.97% to $597.0 million in 2017, then dropped by 1.17% to $590.0 million in 2018.
• According to Business Quant data, Work In Process over the past three periods registered $590.0 million, $609.0 million, and $605.0 million for Q4 2018, Q3 2018, and Q2 2018 respectively.